How to buy Gilead Sciences (GILD) stock from India

Yes, an Indian resident can buy Gilead Sciences — legally, in US dollars, under the RBI's Liberalised Remittance Scheme (LRS). The buying is the easy 10%. The 90% that decides your outcome is tax, estate-tax exposure, and position sizing. GILD pays a real, regularly-raised dividend, so US withholding and Form 67 paperwork are part of the deal.

The 30-second version

• Legal and simple. Buy GILD via IBKR, Rovia, INDmoney, or Vested. Whole shares or a fractional rupee amount.
• Dividend matters here. GILD yields roughly 3-4% and has raised the payout almost every year since 2015. That income comes with 25% US withholding under the India-US DTAA — claim it back via Form 67 (and Form 44 from TY 2026-27).
• India tax on gains: hold more than 24 months and pay 12.5% LTCG (no indexation); sell sooner and pay your slab rate. Section 112, not the friendlier 112A.
• The trap most miss: directly-held GILD is a US-situs asset — above $60,000, your estate faces up to 40% US estate tax, with no India-US treaty relief.
• If your thesis is "biotech," IBB and XBI hold GILD as a top weighting; QQQ, VOO, and VTI hold it in smaller size.

Quick facts

Can an Indian resident buy it?	Yes — legal under the LRS
Ticker / exchange	GILD / Nasdaq
How	IBKR, Rovia, INDmoney, or Vested
Minimum	A fraction of one share (fractional = exact rupee amount)
Dividend	Yes — ≈3-4% yield, quarterly, raised most years since 2015
US dividend withholding	25% under the India-US DTAA (W-8BEN required)
India tax on gains	12.5% LTCG after 24 months; else slab (Section 112)
Estate-tax risk	US-situs above $60k → up to 40%, no treaty relief
Annual compliance	Schedule FA + Form 67 (Form 44 from TY 2026-27)

How to buy it — 3 steps

1. Open an account and finish KYC. Use IBKR for the widest access and best execution, Rovia for a combined RSU + LRS experience, or INDmoney / Vested for a simple India-funded flow. File your W-8BEN during onboarding — this brings US dividend withholding down to 25% under the India-US treaty; skip it and you pay 30%. New to this? See how to invest in US stocks from India.
2. Fund it via the LRS. Remit from your Indian bank under the LRS (cap: $250,000 per financial year). 20% TCS applies above ten lakh rupees in a year — a creditable prepayment, not a cost. See LRS explained and the LRS and TCS calculator. For the full compliance picture, see the LRS + TCS + Schedule FA trifecta.
3. Place the order. GILD typically trades in the eighty-to-one-thirty dollar range, so a whole share is affordable; fractional lets you put in an exact rupee amount.

The tax — dividend side

GILD pays roughly $3.20 a share per year (verify the live rate in the widget — Gilead has raised the quarterly dividend nearly every year since 2015). That flows through two layers of tax:

Layer	What happens	Rate
US side	Withheld at source by the broker	25% (with W-8BEN; 30% without)
India side	Added to total income and taxed at slab	Slab
Relief	Foreign Tax Credit claimed via Form 67	Up to the 25% already withheld

Worked example. Hold 100 GILD shares paying $3.20 a year → $320 gross dividend. US withholds 25% = $80; you receive $240 net. In India, the full $320 (at the SBI TT rate) is added to your slab income. At a 30% slab, India tax before credit is about $96; you claim the $80 paid to the US via Form 67, leaving a net India top-up of roughly $16. From TY 2026-27 the workflow shifts from Form 67 alone to Form 67 plus Form 44 — same idea, more granular reporting. Full walk-through: dividend withholding and Form 67 and the Form 67 guide.

The tax — capital-gains side

Gains tax hits on exit, under Section 112 (foreign shares don't get the friendlier Section 112A treatment Indian-listed equity enjoys):

Holding period	Treatment	Rate
24 months or less	Short-term	Slab rate (up to ≈30% plus surcharge)
More than 24 months	Long-term	12.5%, no indexation

Worked example. Buy 20 shares at $90 when USD/INR is 93 → cost 1,67,400 rupees. Sell 28 months later at $120 when USD/INR is 95 → proceeds 2,28,000 rupees. Taxable gain 60,600 rupees; LTCG at 12.5% = 7,575 rupees. The gain is computed in rupees, so a weaker rupee at sale amplifies the reported gain. Model your own with the US capital-gains calculator; full rules in how US stocks are taxed in India. The India-US tax treaty (DTAA) guide covers dividend withholding relief and treaty benefits.

The $60,000 estate-tax trap

Directly-held GILD is a US-situs asset. If the holder dies with more than $60,000 of US-situs assets, the estate faces US estate tax up to 40% — and the India-US treaty does not cover estate tax, so there's no credit or relief. The fix (holding through pooled or fund structures) has to be a deliberate choice made before the position gets large. Full detail: the $60,000 estate-tax trap.

Buy the stock, or get Gilead through an ETF?

If you want…	Best route
A concentrated bet on HIV franchise and lenacapavir	GILD directly
Broad biotech exposure with GILD as a top weight	IBB or XBI
"US large-cap, GILD included" without single-stock risk	VOO, VTI, or QQQ
The least single-stock risk	A broad ETF

GILD sits inside QQQ, VOO, and VTI at a small weight, and shows up as a top holding in biotech ETFs IBB and XBI. Compare in direct stocks vs US ETFs and best US ETFs for Indian investors; the broader case is in US ETFs for Indians.

The business in one screen

What it is: Gilead is a specialty biopharma anchored by the HIV franchise — Biktarvy is the world's most-prescribed HIV regimen and the Descovy backbone covers treatment and prevention. Around it sit Yeztugo (lenacapavir), the twice-yearly injectable launched in 2025 for HIV prevention; Trodelvy in oncology (TNBC, urothelial); the Kite cell-therapy unit (Yescarta, Tecartus); and a declining Veklury tail.

Bull case	Bear case
HIV franchise is a sticky annuity with Biktarvy at the core	Biktarvy patent cliff approaching in the early 2030s (around 2033)
Yeztugo is a generational HIV-prevention asset — six-month dosing	Lenacapavir launch execution and access pricing are real risks
Trodelvy expanding into more solid-tumour indications	Cell-therapy (Kite) disappointments have weighed on the pipeline
Deep oncology pipeline plus dividend hikes since 2015	Veklury revenue declining as COVID demand fades
Dividend royalty supports total return even in flat tape	M&A discipline question marks after several mixed deals

Exact valuation is in the live widget — a defensive cash-generating biotech with one major launch to prove.

Our take

Verdict: BUY — lenacapavir (Yeztugo) is one of the most significant advances in infectious disease medicine in a generation, the HIV prevention market is enormous and underpenetrated, and Gilead's 3-4% dividend provides a durable income floor while the commercial launch ramps.

• PURPOSE trials were paradigm-shifting. Lenacapavir demonstrated 96-100% efficacy for HIV prevention with twice-yearly dosing in the PURPOSE 1 and 2 trials. There is no precedent in HIV prevention for this level of efficacy at this dose frequency. The FDA approval and commercial launch (branded Yeztugo) represent a category-defining product.
• PrEP is a massive underpenetrated market. An estimated 1.2 million Americans qualify for HIV PrEP under CDC guidelines; only about 400,000 are currently treated. Twice-yearly dosing eliminates the daily adherence barrier that limits the oral-pill market. International access programs in low-income countries expand the total impact further.
• Biktarvy cliff is further away than bears assume. Core patent protection on Biktarvy extends to 2033+, with formulation and method patents providing further runway. Lenacapavir's success also creates a treatment pipeline (not just prevention) that Gilead has not yet fully priced.
• Dividend is a free carry while the commercial launch ramps. The 3-4% yield, consistently raised since 2015, means Indian investors collect real USD income while waiting for lenacapavir to scale. File Form 67 annually to reclaim the 25% US withholding — the amounts are material over a multi-year hold.

Compliance note. Vested.blog is not a SEBI-registered Research Analyst. The above is an editorial opinion for educational illustration only — not investment advice and not a regulated stock recommendation. Vested.blog is published by Rovia; the publisher and its affiliates may hold positions in stocks discussed. Make your own decisions or consult a SEBI-registered advisor.

Risks to size for

• Patent cliff and pipeline gap: Biktarvy protection runs out in the early 2030s; if lenacapavir and Trodelvy don't fill the hole, the dividend coverage story narrows.
• Launch risk on Yeztugo: long-acting HIV prevention needs payer and PrEP-programme uptake; pricing pushback delays the catalyst.
• Currency: your return is in USD but you spend rupees — see the rupee-dollar effect.

Two things people forget

• Schedule FA + Form 67: disclose GILD in Schedule FA of your ITR every year you hold it — even if bought and sold within the year, even at a loss. Non-disclosure carries Black Money Act penalties. Because GILD pays a dividend, also file Form 67 (plus Form 44 from TY 2026-27) to claim back the 25% US withholding. Use the Schedule FA helper. See the Schedule FA disclosure guide for full details.
• Position size: GILD is a single specialty-biotech name with one major launch in front of it. Size as a high-conviction income satellite, not a substitute for a broad ETF.

Bottom line

Buying GILD from India is easy and legal. What needs thought is that GILD is a Section-112 capital-gains play (12.5% after 24 months) plus a dividend-paying US-situs asset with recurring 25% withholding, an annual Form 67 (and Form 44 from TY 2026-27) workflow, and a $60k estate-tax trap on top. The story is an HIV annuity with lenacapavir as the swing factor — sized as an income-tilted satellite, it has a place; sized like a megacap, it doesn't. For accounts and options, start at the US investing hub.

Related stocks and ETFs to consider

Indian investors researching Gilead Sciences often also look at:

• Tesla from India — EVs, energy storage, and FSD/robotaxi ambitions
• Netflix from India — streaming video and live events
• Visa from India — global payment network

---

This article is general information, not personalised investment, tax, or legal advice. Rules, rates, and thresholds described here are as of 2026 and can change; verify the current position and consult a qualified advisor before acting.